ESPERION THERAPEUTICS INC (ESPR)
US29664W1053 - Common Stock
Taking everything into account, ESPR scores 2 out of 10 in our fundamental rating. ESPR was compared to 198 industry peers in the Pharmaceuticals industry. ESPR may be in some trouble as it scores bad on both profitability and health. ESPR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ESPR has reported negative net income.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
In the past 5 years ESPR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -101.68%, ESPR is doing worse than 82.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.68% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ESPR's Gross Margin of 62.83% is fine compared to the rest of the industry. ESPR outperforms 67.69% of its industry peers.
In the last couple of years the Gross Margin of ESPR has declined.
The Profit Margin and Operating Margin are not available for ESPR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ESPR has been increased compared to 1 year ago.
ESPR has more shares outstanding than it did 5 years ago.
ESPR has a worse debt/assets ratio than last year.
2.2 Solvency
ESPR has an Altman-Z score of -11.85. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ESPR (-11.85) is worse than 79.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.85 |
ROIC/WACCN/A
WACC8.2%
2.3 Liquidity
ESPR has a Current Ratio of 1.29. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ESPR (1.29) is worse than 78.46% of its industry peers.
A Quick Ratio of 0.87 indicates that ESPR may have some problems paying its short term obligations.
The Quick ratio of ESPR (0.87) is worse than 83.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
ESPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.28%, which is quite impressive.
ESPR shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.31%.
ESPR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.03% yearly.
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q34.21%
Revenue 1Y (TTM)54.31%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Revenue growth Q2Q71.54%
3.2 Future
Based on estimates for the next years, ESPR will show a very strong growth in Earnings Per Share. The EPS will grow by 37.22% on average per year.
ESPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.55% yearly.
EPS Next Y80.56%
EPS Next 2Y42.3%
EPS Next 3Y36.36%
EPS Next 5Y37.22%
Revenue Next Year135.08%
Revenue Next 2Y86.2%
Revenue Next 3Y80.13%
Revenue Next 5Y60.55%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESPR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ESPR's earnings are expected to grow with 36.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.3%
EPS Next 3Y36.36%
5. Dividend
5.1 Amount
ESPR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ESPERION THERAPEUTICS INC
NASDAQ:ESPR (5/3/2024, 6:07:02 PM)
After market: 2.08 0 (0%)2.08
+0.02 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap393.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.68% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.29 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y80.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)54.31%
Revenue growth 3Y-20.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y